Trospium

DB00209ApprovedInvestigationalSmall moleculeAnticholinergic AgentsMuscarinic Antagonists

Trospium is an antimuscarinic agent used to treat the symptoms of overactive bladder (OAB). An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination.

Chemical structure of Trospium
Mechanism
Curator reviewed
Primary indication
Trospium is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.Curator reviewed · 2 structured indications
Formula / weight
C25H30NO3 · 392.518 g/mol (avg)
First approval
Canada, 2010 · United States, 2007
Brand names
  • Cobenfy

Resolves to

Compound
UNIIT4Y8ORK057CAS47608-32-2ChEMBLCHEMBL1888176ChEBI145791PubChem5284632KEGGD01103
Clinical / RWD
RxNorm236778ATCA03DA06ATCG04BD09PharmGKBPA164748976
Structure
InChIKeyOYYDSUSKLWTMMQ-JKHIJQBDSA-NSMILES[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1)[N+]21CCCC1
Targets
P08172CHRM2P20309CHRM3P08912CHRM5P11229CHRM1

What you can answer from here — as of September 13, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
697Drug interactionsStructured to mechanism, not free text
Sign in
53Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
3ContraindicationsEach with its own population and attribute set
Sign in
207Marketed productsAcross 10 countries and 49 labellers
Sign in
2ATC codesIncluding every combination product, plus 25 drug categories
Sign in
14+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Trospium, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In